AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35439461 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience training (eight-week resilience training; n = 34)
Number of subjects: 68
Study 35439461 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (eight-week health education; n = 34)
Number of subjects: 68
Study 33030881 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol plus Foley bulb (100 micrograms)
Number of subjects: 2237
Study 33030881 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol alone (100 micrograms)
Number of subjects: 2237
Study 36109766 — intervention group
Group type: EXPERIMENTAL
Intervention: RDT decisional algorithm (RDT-DA) arm
Number of subjects: 0
Study 36109766 — intervention group
Group type: EXPERIMENTAL
Intervention: e-algorithm arm
Number of subjects: 0
Study 36109766 — intervention group
Group type: COMPARATOR
Intervention: Control arm (IMCI standard of care)
Number of subjects: 0
Study 33706770 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Learning Collaborative (VLC)
Number of subjects: 48
Study 33706770 — intervention group
Group type: COMPARATOR
Intervention: Technical Assistance (TA)
Number of subjects: 48
Study 32579812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schedules (16 hours or less shifts)
Number of subjects: 0
Study 32579812 — intervention group
Group type: COMPARATOR
Intervention: Control schedules (24 hours or more shifts)
Number of subjects: 0
Study 35211010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine at 0.8 μg.kg−1 for 10 min
Number of subjects: 45
Study 35211010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine at 1 μg.kg−1
Number of subjects: 45
Study 35211010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexmedetomidine at 4 μg.kg−1
Number of subjects: 45
Study 33188392 — intervention group
Group type: COMPARATOR
Intervention: Dietary concentration of ergovaline: 0, 0.862, and 1.282 mg/kg of diet (experiment 1)
Number of subjects: 16
Study 33188392 — intervention group
Group type: COMPARATOR
Intervention: Endophyte-infected seeds providing ergovaline dosage of 15 μg/kg BW (experiment 2)
Number of subjects: 16
Study 33509602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet pressure of SBP + 75 mm Hg (group I)
Number of subjects: 150
Study 33509602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet pressure of SBP + 100 mm Hg (group II)
Number of subjects: 150
Study 33509602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet pressure of SBP + 150 mm Hg (group III)
Number of subjects: 150
Study 32568429 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal FEF75
Number of subjects: 126
Study 32568429 — intervention group
Group type: EXPERIMENTAL
Intervention: Very abnormal FEF75
Number of subjects: 126
Study 35857196 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin and NSAIDs
Number of subjects: 220
Study 35857196 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 220
Study 33793734 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate total-body CT (iTBCT)
Number of subjects: 928
Study 33793734 — intervention group
Group type: COMPARATOR
Intervention: Standard work-up (STWU)
Number of subjects: 928
Study 35246418 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial tumour site
Number of subjects: 1631
Study 35246418 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor histological response
Number of subjects: 1631
Study 35246418 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <12 years
Number of subjects: 1631
Study 35246418 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >18 years
Number of subjects: 1631
Study 33313847 — intervention group
Group type: EXPERIMENTAL
Intervention: MISTIE procedure with recombinant tissue plasminogen activator
Number of subjects: 0
Study 33313847 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis for large intraventricular hemorrhage
Number of subjects: 0
Study 35150143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-curcumin (160 mg for 10 days)
Number of subjects: 14
Study 33306635 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital PET/CT
Number of subjects: 64
Study 33306635 — intervention group
Group type: COMPARATOR
Intervention: Analog PET/CT
Number of subjects: 64
Study 33306635 — intervention group
Group type: COMPARATOR
Intervention: Both systems
Number of subjects: 64
Study 32890472 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT + LLLT
Number of subjects: 40
Study 32890472 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT
Number of subjects: 40
Study 32890472 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT
Number of subjects: 40
Study 32890472 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 32890472 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT group
Number of subjects: 40
Study 32890472 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT group
Number of subjects: 40
Study 32890472 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT + LLLT group
Number of subjects: 40
Study 36199630 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/kg lidocaine (L0.5)
Number of subjects: 0
Study 36199630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg lidocaine (L1.0)
Number of subjects: 0
Study 36199630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg lidocaine (L1.5)
Number of subjects: 0
Study 36199630 — intervention group
Group type: COMPARATOR
Intervention: saline (L0)
Number of subjects: 0
Study 32572778 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus aurantium essential oil inhalation for 15–20 min about 60 min before angiography
Number of subjects: 80
Study 32572778 — intervention group
Group type: COMPARATOR
Intervention: Distilled water inhalation (control group)
Number of subjects: 80
Study 32893372 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallstone disease
Number of subjects: 0
Study 32893372 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically elevated body mass index (BMI)
Number of subjects: 0
Study 32893372 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CRP concentrations
Number of subjects: 0
Study 32893372 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0
Study 35798988 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (n = 172)
Number of subjects: 344
Study 35798988 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 172)
Number of subjects: 344
Study 32768315 — intervention group
Group type: EXPERIMENTAL
Intervention: High EAA (0.3 g/kg, 23.5 ± 2.54 g)
Number of subjects: 19
Study 32768315 — intervention group
Group type: COMPARATOR
Intervention: Standard EAA (0.1 g/kg, 7.87 ± 0.87 g)
Number of subjects: 19
Study 35917753 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmentally Adapted Cognitive Processing Therapy (D-CPT)
Number of subjects: 44
Study 35917753 — intervention group
Group type: COMPARATOR
Intervention: Waitlist with treatment advice (WL/TA)
Number of subjects: 44
Study 33727428 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 60
Study 33727428 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride
Number of subjects: 60
Study 33727428 — intervention group
Group type: COMPARATOR
Intervention: CEPS patients
Number of subjects: 60
Study 36104971 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity (FA)
Number of subjects: 26
Study 36104971 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity 60-minute FA
Number of subjects: 26
Study 36104971 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute FA
Number of subjects: 26
Study 36104971 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity FA
Number of subjects: 26
Study 36104971 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute low-intensity FA
Number of subjects: 26
Study 33626021 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 120
Study 33626021 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 120
Study 33626021 — intervention group
Group type: COMPARATOR
Intervention: Stress ball
Number of subjects: 120
Study 33626021 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 33183660 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIpostC)
Number of subjects: 106
Study 33183660 — intervention group
Group type: COMPARATOR
Intervention: Sham remote ischemic postconditioning
Number of subjects: 106
Study 35351054 — intervention group
Group type: EXPERIMENTAL
Intervention: KiVa anti-bullying programme
Number of subjects: 13000
Study 35351054 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 13000
Study 33610906 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassionate Focused Therapy (CFT)
Number of subjects: 74
Study 33610906 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 74
Study 33610906 — intervention group
Group type: COMPARATOR
Intervention: PTSD
Number of subjects: 74
Study 33610906 — intervention group
Group type: COMPARATOR
Intervention: CPTSD
Number of subjects: 74
Study 33610906 — intervention group
Group type: COMPARATOR
Intervention: Traumatic stress
Number of subjects: 74
Study 36445384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 2163
Study 35106332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Hip External Fixator (DHEF)
Number of subjects: 46
Study 35106332 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 46
Study 35428718 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX+ETN combination therapy
Number of subjects: 851
Study 33750279 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in research physicians
Number of subjects: 229
Study 33750279 — intervention group
Group type: COMPARATOR
Intervention: Trust in primary care providers
Number of subjects: 229
Study 33750279 — intervention group
Group type: COMPARATOR
Intervention: Trust in medical research processes
Number of subjects: 229
Study 32843021 — intervention group
Group type: EXPERIMENTAL
Intervention: Holidaily app intervention (IG) - two weeks pre-vacation access
Number of subjects: 0
Study 32843021 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group (CG) - access to Holidaily two weeks post-vacation
Number of subjects: 0
Study 35232782 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 622
Study 33442924 — intervention group
Group type: COMPARATOR
Intervention: Bilateral formula-based ECT (BT)
Number of subjects: 29
Study 33442924 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral formula-based ECT (RUL)
Number of subjects: 29
Study 36074703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted carbon nanoparticle suspension (CNS) mapping
Number of subjects: 330
Study 36074703 — intervention group
Group type: COMPARATOR
Intervention: Dual tracer-guided mapping with CNS plus indocyanine green (ICG)
Number of subjects: 330
Study 35421019 — intervention group
Group type: EXPERIMENTAL
Intervention: Camelina sativa oil (CSO) supplement for 12 weeks
Number of subjects: 46
Study 35421019 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 46
Study 32143716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (POMj)
Number of subjects: 9
Study 32143716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9
Study 34719994 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 36
Study 34719994 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 36
Study 34719994 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36
Study 33074284 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, 15 mg daily
Number of subjects: 3699
Study 33074284 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, 100 mg daily
Number of subjects: 3699
Study 34967184 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D with physical activity (VDPA arm)
Number of subjects: 46
Study 34967184 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D alone (VD arm)
Number of subjects: 46
Study 33570584 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral age-related hearing loss (ARHL) in the physical frailty group (96 out of 361, 26.6%)
Number of subjects: 1929
Study 33570584 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral age-related hearing loss (ARHL) in the cognitive frailty group (40 out of 103, 38.8%)
Number of subjects: 1929
Study 33570584 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related central auditory processing disorder (CAPD) in the physical frailty group (62 out of 361, 17.2%)
Number of subjects: 1929
Study 33570584 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related central auditory processing disorder (CAPD) in the cognitive frailty group (28 out of 103, 27.2%)
Number of subjects: 1929
Study 33570584 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related CAPD
Number of subjects: 1929
Study 33570584 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic Sentence Identification With the Ipsilateral Competitive Message scores
Number of subjects: 1929
Study 33570584 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral ARHL
Number of subjects: 1929
Study 32065623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg zilucoplan SC daily
Number of subjects: 44
Study 32065623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg zilucoplan SC daily
Number of subjects: 44
Study 32065623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32065623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg zilucoplan
Number of subjects: 44
Study 32065623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg zilucoplan
Number of subjects: 44
Study 33474611 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT‐AFL
Number of subjects: 159
Study 33474611 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT‐AFL + rPDT
Number of subjects: 159
Study 34662341 — intervention group
Group type: EXPERIMENTAL
Intervention: Information structuring (S)
Number of subjects: 256
Study 34662341 — intervention group
Group type: COMPARATOR
Intervention: Empathy (E)
Number of subjects: 256
Study 33306586 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole eggs + RT (n = 15)
Number of subjects: 30
Study 33306586 — intervention group
Group type: COMPARATOR
Intervention: Egg whites + RT (n = 15)
Number of subjects: 30
Study 33306586 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole eggs + RT
Number of subjects: 30
Study 33306586 — intervention group
Group type: COMPARATOR
Intervention: Egg whites + RT
Number of subjects: 30
Study 33306586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 32285955 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg dose)
Number of subjects: 133
Study 35197100 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated CMCA-Connect intervention
Number of subjects: 20
Study 35942408 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus split-course radiotherapy
Number of subjects: 44
Study 35942408 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab alone
Number of subjects: 44
Study 35257648 — intervention group
Group type: EXPERIMENTAL
Intervention: digital cognitive behavioral therapy for insomnia (dCBT-I)
Number of subjects: 658
Study 35257648 — intervention group
Group type: COMPARATOR
Intervention: sleep education control
Number of subjects: 658
Study 33546067 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded motor imagery (GMI) training, performed at home for 8 weeks, 30 minutes a day.
Number of subjects: 42
Study 33546067 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 42
Study 32932175 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine
Number of subjects: 0
Study 32932175 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine
Number of subjects: 0
Study 32932175 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 0
Study 32932175 — intervention group
Group type: COMPARATOR
Intervention: GBCM-exposed RBCs
Number of subjects: 0
Study 32932175 — intervention group
Group type: COMPARATOR
Intervention: GBCM-exposed K562 cancer cells
Number of subjects: 0
Study 32932175 — intervention group
Group type: COMPARATOR
Intervention: GBCM (all three types)
Number of subjects: 0
Study 36066179 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible tip bougie
Number of subjects: 160
Study 36066179 — intervention group
Group type: COMPARATOR
Intervention: Standard bougie
Number of subjects: 160
Study 33387920 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime sleep duration
Number of subjects: 36
Study 33387920 — intervention group
Group type: EXPERIMENTAL
Intervention: Social jetlag
Number of subjects: 36
Study 33387920 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotype
Number of subjects: 36
Study 33387920 — intervention group
Group type: EXPERIMENTAL
Intervention: Time interval >2 h between last meal and sleep onset
Number of subjects: 36
Study 35788070 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (daily tablet for 6 months)
Number of subjects: 140
Study 35788070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily tablet for 6 months)
Number of subjects: 140
Study 33620905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (100 mg) twice-daily for 5 days
Number of subjects: 164
Study 33620905 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice-daily for 5 days
Number of subjects: 164
Study 32430459 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-related traits (including T2DM)
Number of subjects: 898130
Study 32430459 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-related traits (including T1DM, T2DM)
Number of subjects: 898130
Study 32430459 — intervention group
Group type: EXPERIMENTAL
Intervention: Other diseases/traits (including inflammatory bowel disease, breast cancer, lung cancer, asthma, smoking)
Number of subjects: 898130
Study 32430459 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs (fostamatinib, zinc)
Number of subjects: 898130
Study 36008574 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y90) radioembolization with chemotherapy
Number of subjects: 60
Study 36008574 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 60
Study 34769814 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 157
Study 34769814 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 157
Study 35072717 — intervention group
Group type: COMPARATOR
Intervention: Information from electronic health care records
Number of subjects: 3543
Study 35072717 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps from applications on their phone
Number of subjects: 3543
Study 35072717 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint attributes
Number of subjects: 3543
Study 35072717 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusters of consumers based on willingness to share
Number of subjects: 3543
Study 33432643 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (booklet and coaching on postoperative days 2, 3, and 7)
Number of subjects: 220
Study 33432643 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 220
Study 33432643 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Number of subjects: 220
Study 33463497 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal‐directed therapy (EGDT)
Number of subjects: 40
Study 33463497 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided fluid resuscitation
Number of subjects: 40
Study 35941373 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepinemab
Number of subjects: 265
Study 35941373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 33635156 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth program for hearing aid management
Number of subjects: 82
Study 33635156 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 82
Study 34684525 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon (246 g fillet/day for 8 weeks, 3 days per week)
Number of subjects: 49
Study 34684525 — intervention group
Group type: COMPARATOR
Intervention: Yellowstripe scad (385 g whole fish/day for 8 weeks, 3 days per week)
Number of subjects: 49
Study 34090854 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced, web-based transfer training module
Number of subjects: 72
Study 34090854 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WLCG)
Number of subjects: 72
Study 33263234 — intervention group
Group type: EXPERIMENTAL
Intervention: TLAe (20 mg/kg subcutaneous)
Number of subjects: 91
Study 33263234 — intervention group
Group type: COMPARATOR
Intervention: CEF (125 mg/quarter intramammary)
Number of subjects: 91
Study 33764324 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone 100 mg/d for 8 weeks
Number of subjects: 38
Study 33764324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32464280 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily for 3 weeks on/1 week off
Number of subjects: 66
Study 32464280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 35179193 — intervention group
Group type: COMPARATOR
Intervention: Almonds (300 kcal/d)
Number of subjects: 180
Study 35179193 — intervention group
Group type: EXPERIMENTAL
Intervention: French fries (potato group, 300 kcal/d)
Number of subjects: 180
Study 35179193 — intervention group
Group type: EXPERIMENTAL
Intervention: French fries with herb/spices mix (potato + herb/spices group, 300 kcal/d)
Number of subjects: 180
Study 33442242 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedication review (TMR)
Number of subjects: 16
Study 32819304 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Number of subjects: 17
Study 32819304 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity, continuous aerobic training (CMIT)
Number of subjects: 17